Amicus director receives cash in BioMarin merger
Amicus Therapeutics director Michael Aaron Kelly disposed of his equity in connection with the acquisition of Amicus by BioMarin Pharmaceutical.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Amicus Therapeutics director Michael Aaron Kelly disposed of his equity in connection with the acquisition of Amicus by BioMarin Pharmaceutical. He surrendered 72,468 shares of Common Stock at $14.50 per share, including 52,054 shares of Common Stock and 20,414 restricted stock units that vested at closing.
On the same date, several fully vested stock option grants covering 74,872, 42,467, 30,474, 45,423 and 36,111 shares of Common Stock were cancelled and converted into cash. For each option, the cash payment equaled the difference between the $14.50 merger price and the option’s exercise price, multiplied by the number of option shares. Following these transactions, the filing shows no remaining holdings from these awards.
Insider Trade Summary
Disposition: 301,815 shares
Disposition
6 txns
Insider
Kelly Michael Aaron
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Options (right to buy) | 36,111 | $0.00 | $0.00 |
| Disposition | Stock Options (right to buy) | 45,423 | $0.00 | $0.00 |
| Disposition | Stock Options (right to buy) | 30,474 | $0.00 | $0.00 |
| Disposition | Stock Options (right to buy) | 42,467 | $0.00 | $0.00 |
| Disposition | Stock Options (right to buy) | 74,872 | $0.00 | $0.00 |
| Disposition | Common Stock | 72,468 | $14.50 | $1.05M |
Holdings After Transaction:
Stock Options (right to buy) — 0 contracts (Direct);
Common Stock — 0 shares (Direct)
Footnotes (4)
- F1. The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 52,054 shares of Common Stock and 20,414 restricted stock units (which vested in full in connection with consummation of the Merger).
- F2. In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option.
- F3. Each Option was fully vested.
- F4. Each Option vested in full in connection with consummation of the Merger.
Key Figures
Common shares disposed: 72,468 shares at $14.50
Common stock component: 52,054 shares
Restricted stock units vested: 20,414 RSUs
+5 more
8 metrics
Common shares disposed
72,468 shares at $14.50
Common Stock disposed in connection with BioMarin merger
Common stock component
52,054 shares
Portion of 72,468 securities identified as Common Stock in footnote
Restricted stock units vested
20,414 RSUs
RSUs that vested in full when the merger was consummated
Option grant 1 shares and strike
74,872 options at $5.96
Stock Options (right to buy) cancelled and paid in cash
Option grant 2 shares and strike
42,467 options at $10.27
Stock Options (right to buy) cancelled and paid in cash
Option grant 3 shares and strike
30,474 options at $12.62
Stock Options (right to buy) cancelled and paid in cash
Option grant 4 shares and strike
45,423 options at $8.55
Stock Options (right to buy) cancelled and paid in cash
Option grant 5 shares and strike
36,111 options at $10.71
Stock Options (right to buy) cancelled and paid in cash
Key Terms
Disposition to issuer, restricted stock units, stock option, Merger, +1 more
5 terms
Disposition to issuer financial
"transaction_code_description": "Disposition to issuer""
restricted stock units financial
"20,414 restricted stock units (which vested in full in connection"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
stock option financial
"each reported stock option ("Option") was cancelled and converted"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
Merger financial
"consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger")"
A merger is when two companies combine into a single business, with ownership and control reorganized so they operate as one entity. For investors it matters because mergers can change the value and risk of holdings—shares may be exchanged, diluted, or rise if the combined company saves costs or gains market power, and the deal often depends on regulatory approval and successful integration like two households joining resources and routines.
exercise price financial
"the excess of (i) $14.50 per share over (ii) the exercise price payable per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Amicus Therapeutics (FOLD) director Michael Aaron Kelly report in this Form 4?
He reported disposing of Amicus equity in connection with the BioMarin acquisition. The filing covers 72,468 shares of Common Stock and multiple stock option awards that were cancelled and paid out in cash at the merger closing.
What happened to Michael Aaron Kelly’s Amicus (FOLD) stock options in the BioMarin merger?
Each reported Amicus stock option was cancelled at closing and converted into cash. The cash amount equaled the excess of the $14.50 merger price over the option’s exercise price, multiplied by the number of shares subject to that option grant.
Were the Amicus Therapeutics (FOLD) stock options vested before the merger closed?
Yes. The footnotes state that each reported stock option was fully vested. For some grants, vesting occurred earlier; for others, vesting was triggered in full upon consummation of the BioMarin-Amicus merger, before being cancelled for a cash payment.
Did restricted stock units for Amicus Therapeutics (FOLD) vest in the BioMarin deal?
Yes. The filing notes that 20,414 restricted stock units vested in full when the BioMarin acquisition closed. Those units are included within the 72,468 Amicus Common Stock securities that were disposed of in connection with consummation of the merger transaction.
Does the Form 4 indicate remaining Amicus (FOLD) holdings after these transactions?
The reported awards show zero total shares following these transactions. The Common Stock position and each listed option grant report 0.0000 shares remaining, reflecting their disposal or cancellation as part of the BioMarin acquisition of Amicus Therapeutics.
AI-generated analysis. How Rhea-AI works. Not financial advice.
